Tags

Type your tag names separated by a space and hit enter

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Antimicrob Agents Chemother. 2015 Oct; 59(10):6605-7.AA

Abstract

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA rhumphries@mednet.ucla.edu jfhindler@mednet.ucla.edu.Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA rhumphries@mednet.ucla.edu jfhindler@mednet.ucla.edu.Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26195508

Citation

Humphries, Romney M., et al. "First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella Pneumoniae Isolate." Antimicrobial Agents and Chemotherapy, vol. 59, no. 10, 2015, pp. 6605-7.
Humphries RM, Yang S, Hemarajata P, et al. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrob Agents Chemother. 2015;59(10):6605-7.
Humphries, R. M., Yang, S., Hemarajata, P., Ward, K. W., Hindler, J. A., Miller, S. A., & Gregson, A. (2015). First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrobial Agents and Chemotherapy, 59(10), 6605-7. https://doi.org/10.1128/AAC.01165-15
Humphries RM, et al. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella Pneumoniae Isolate. Antimicrob Agents Chemother. 2015;59(10):6605-7. PubMed PMID: 26195508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. AU - Humphries,Romney M, AU - Yang,Shangxin, AU - Hemarajata,Peera, AU - Ward,Kevin W, AU - Hindler,Janet A, AU - Miller,Shelley A, AU - Gregson,Aric, Y1 - 2015/07/20/ PY - 2015/05/17/received PY - 2015/07/11/accepted PY - 2015/7/22/entrez PY - 2015/7/22/pubmed PY - 2016/7/7/medline SP - 6605 EP - 7 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 59 IS - 10 N2 - Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/26195508/First_Report_of_Ceftazidime_Avibactam_Resistance_in_a_KPC_3_Expressing_Klebsiella_pneumoniae_Isolate_ DB - PRIME DP - Unbound Medicine ER -